Business
AGM Statement and Directorate Succession Planning
AGM Statement and Directorate Succession Planning.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n\n\nCreo Medical Group plc\n(\"Creo\" the \"Company\" or the \"Group\")\n \nAGM Statement\nand\nDirectorate Succession Planning\n \nCreo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, provides an update to shareholders ahead of its Annual General Meeting ('AGM') being held today at Creo House, Beaufort Park, Beaufort Park Way, Chepstow NP16 5UH at 10:00am.\n \nChair's AGM statement\n \n\"The past 12 months have shown continued momentum in Creo's journey towards becoming a mature, international medtech group. Using the financial resources provided by our March 2023 equity raise, we have continued to execute on all fronts of our strategy. This has included the launch of Speedboat UltraSlim, accelerated in the EU by 18 months, quickly being followed by the product being used in the US, APAC and Latin America, with exceptional clinician feedback. We have been delighted to see the investment in our Pioneer training programme continue to deliver a growing number of worldwide users, with a 119% increase over the course of 2023.\n \n\"The recent NHS Supply Chain data, which confirmed net cash savings of £687k from 130 Speedboat procedures at one NHS Trust, was a fantastic validation of the difference our technology can make to healthcare systems in addition to improving patient outcomes. We look forward to working alongside NHS Supply Chain as they promote the value proposition of Speedboat to Trusts around the country.\n \n\"We were also proud to be named as a recipient of the King's Award for Enterprise in Innovation last month, providing recognition of our team's hard work and dedication to build a truly innovative technology platform. The potential of Creo's technology has also been demonstrated through our Kamaptive partnerships, as MicroBlate Flex was recently used to treat a cancerous lung nodule in the same sitting as a diagnosis performed with a robotic platform, in a world's-first combined procedure at the Royal Brompton Hospital.\n \n\"The team has worked hard to keep disciplined control over costs, even as the business has continued to grow, which contributed to a reduced operating loss for the financial year ended 31 December 2023, and we continue to progress towards our ...